项目编号 PRJEB23709
项目标题 Biomarkers of response and resistance to checkpoint blockade immunotherapy in metastatic melanoma
数据类型 Other
样品范围 Monoisolate
描述信息 Identifying the mechanistic features that determine a cancer patient's response to immune checkpoint inhibitors is a critical step towards improving the efficacy of current therapies and optimising the design of clinical trials for next-generation drugs. Here, we investigated the transcriptomic and immunophenotypic profiles of metastatic melanoma patients treated with anti-PD-1 alone or combined anti-PD-1 and anti-CTLA-4 immunotherapy. Effector T-cells are essential for increased anti-cancer activity, favouring better survival outcomes in patients treated with anti-PD-1 monotherapy. In contrast, response to combined anti-PD-1 and anti-CTLA-4 immunotherapy relied upon memory cytotoxic and helper T-cell populations. Patients with resistance to immune checkpoint blockade exploited the metabolic and hypoxia-mediated pathways to alter tumour microenvironment causing impairment of T-cell trafficking and function. Our findings provide a strong rationale for stratifying patients based on molecular profiles that determine response and resistance to anti-PD1 alone or in combination with anti-CTLA-4 immunotherapy.
出版信息
PubMed ID 文章标题 杂志名称 Doi 发表年份
30753825 Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer cell 2019
发布日期 2019-02-14
提交单位 Melanoma Institute Australia
数据来源 NCBI

项目包含数据信息

资源名称 描述
Experiment (91)  show -